Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile

Nayimisha Balmuri1,2, William Daniel Soulsby3, Victoria Cooley4

  • 1Hospital for Special Surgery, New York, NY, USA. nbalmur1@jhmi.edu.

Insights

Children with polyarticular juvenile idiopathic arthritis (pJIA) in poorer communities experience longer delays in seeking specialist care. This highlights how social determinants of health impact pediatric rheumatology access for pJIA patients.

Area of Science:

  • Pediatric Rheumatology
  • Social Determinants of Health
  • Health Disparities

Background:

  • Social determinants of health significantly influence pediatric conditions, yet their impact on polyarticular juvenile idiopathic arthritis (pJIA) remains unclear.
  • Early intervention in pJIA is crucial for mitigating disease progression and morbidity.
  • Delayed presentation to pediatric rheumatologists can impede timely treatment initiation for pJIA.

Purpose of the Study:

  • To investigate the association between community poverty levels and the time to initial pediatric rheumatology consultation for children diagnosed with pJIA.
  • To analyze how socioeconomic factors, specifically poverty, affect access to specialized care for pediatric arthritis patients.

Main Methods:

  • A cohort study utilizing data from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry.
  • Patient addresses were geocoded to determine community poverty levels, serving as the primary exposure.
  • Time from symptom onset to the first rheumatology visit was the primary outcome, analyzed using Kaplan-Meier and Cox proportional-hazards models.

Main Results:

  • The study included 1684 pJIA patients, with a median age of 7 years at onset; 19% resided in communities with ≥20% poverty.
  • While initial Kaplan-Meier analysis showed no significant difference in presentation time based on poverty level (p=0.6), adjusted Cox models revealed otherwise.
  • Patients in communities with ≥20% poverty were 19% less likely to see a rheumatologist (adjusted HR 0.81, p=0.038) compared to those in lower poverty areas, after controlling for covariates.

Conclusions:

  • Higher community poverty levels are significantly associated with a longer time to presentation for pediatric rheumatology care among children with pJIA.
  • These findings underscore the role of socioeconomic factors as barriers to timely diagnosis and treatment in pediatric rheumatic diseases.
  • Addressing social determinants of health is essential for improving healthcare access and outcomes for children with pJIA.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
57
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
44
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
46
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
152
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
39
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
56